Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jun
07
Today In Oncology
AML All-Oral Regimen Safe and Eases Treatment Administration Burden
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
Overall Survival With EBRT in Hepatocellular Carcinoma
SCLC With Brain-Only Progression Original or Substitute Systemic Therapy With or Without Brain Radiotherapy
Five-Year Survival Analysis: Neoadjuvant Trastuzumab-Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo